Friday, September 7, 2012

DNA Sequencing Market Report Published

For the 3rd time since 2007, Kalorama has completed a full study of the DNA Sequencing market.  The market for DNA Sequencing has slowed a bit as stimulus fund monies were reduced and customers in major research centers cut purchases and used older systems as best they could, but  the introduction of new systems and continued demand will reverse this trend, according to Kalorama Information.  The healthcare market research publisher has reviewed the DNA Sequencing market since 2007 and in its latest study, says that the  introductions of the Ion Torrent PGM, PacBio RS and MiSeq grew the sequencer market 4.6% to $560 million dollars in 2011.    
     More new technologies expected from Ion Torrent as well as Oxford Nanopore may further change the market and introduce price changes, according to Kalorama’s report, DNA Sequencing andEquipment Markets, 3rd Edition.

Market Video

Spending a lot of time doing internal research can be avoided with well-targeted syndicated market research reports.   In many cases (especially in the area of vaccines and diagnostics) the work has been done for you.

An article in the Market Research Beat blog features our parent company Market's video which quickly explains what our company does for clients.   It is quite different from other websites selling content.

Tuesday, September 4, 2012

FDA Encouraging OTC Drug Switches

Ultimately, it's in everyone's interest to reduce healthcare costs.  This includes the Federal Government.  Thus, the FDA though an independent agency, has been encouraging OTC treatments where possible and safe in order to provide more treatments to patients at a lower cost.  They are accomplishing this through regulatory changes.  As commented on in Kalorama's recent report on OTC drugs, the FDA is continuing to review prescription drugs for potential switches...leading to a boost in the OTC market.  Several products are in discussions including those for pain, overactive bladder, an emergency kit for bacterial infections, cholesterol, high blood pressure and migraines.  

The FDA has outlined several methods of improving the flow of switches to the market including new ways of dosing existing Rx products, new indications for Rx products that may be suitable for OTC, and Rx-to-OTC switches for products reaching patent expirations and are OTC compatible.  

A meeting in November 2012 with the FDA will evaluate oxybutynin transdermal system for OTC use as a treatment for overactive bladder in women.

Kalorama Information’s report Over the Counter (OTC) Drug Markets includes incidence of conditions which are often treated with OTC medicines, health statistics related to the industry, birth rates, world population, populations by region and issues affecting the market as a whole. Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets. The market segments provide an overview of demographics, overview of products available in each region, market estimates and forecasts. Additionally, a competitive analysis of leading providers and profiles of providers is covered. Information on the report can be found at: